Patent intelligence · US
US 11505564
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Patent details — US 11505564
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 22, 2022
- Expiration
- Nov 17, 2042
- Applicant
- Compass Pathfinder Limited
- Claims
- 26
- CPC classes
- A61K, A61K47/36, A61K47/38, A61K9/0053
Quick answer
US 11505564 (Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use) is held by Compass Pathfinder Limited. Status: granted. Granted Nov 22, 2022. Expires Nov 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Compass Pathfinder Limited
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K47/36, A61K47/38, A61K9/0053, A61K9/2054
More from Compass Pathfinder Limited
Related pharmaceutical patents in our USPTO index.
-
US 12377112
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
granted -
US 12312375
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted -
US 12186285
Compositions and methods of treatment for tinea pedis
granted -
US 12070594
Biomedical electrode with anti-microbial properties
granted -
US 11970538
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 11939346
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11865179
Progesterone formulations having a desirable PK profile
granted
Frequently asked questions
What is US patent 11505564?
US 11505564 (Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use) is held by Compass Pathfinder Limited. Status: granted. Granted Nov 22, 2022. Expires Nov 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11505564?
Compass Pathfinder Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 100 pharmaceutical patents for this assignee.
When does US 11505564 expire?
Our index shows an expiration date of Nov 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.